

# Resource Summary Report

Generated by [kravitz2](#) on Sep 5, 2026

## DaTo

RRID:SCR\_010280

Type: Tool

---

### Proper Citation

DaTo (RRID:SCR\_010280)

---

### Resource Information

**URL:** <http://bis.zju.edu.cn/DaTo/>

**Proper Citation:** DaTo (RRID:SCR\_010280)

**Description:** A biological database and software tool catalog based on text mined and human annotated url mentions in PubMed abstracts. Data are annotated as to the author's country of origin and url status is checked.

**Abbreviations:** DaTo

**Synonyms:** DA&TO - The Atlas of biology databases and tools, DAandTO, Da&To

**Resource Type:** data or information resource, database

**Keywords:** metadata, catalog, text mining

**Funding:** National Natural Science Foundation of China 30971743;  
National Natural Science Foundation of China 31371328

**Resource Name:** DaTo

**Resource ID:** SCR\_010280

**Alternate IDs:** nlx\_157296

**Record Creation Time:** 20220129T080257+0000

**Record Last Update:** 20260904T000254+0000

---

### Ratings and Alerts

No rating or validation information has been found for DaTo.

No alerts have been found for DaTo.

## Data and Source Information

**Source:** [SciCrunch Registry](#)

## Usage and Citation Metrics

We found 12 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [kravitz2](#) .

Tang Z, et al. (2026) Exposure-Response Analyses of Datopotamab Deruxtecan (Dato-DXd) in Patients with Hormone Receptor (HR) Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer. *Journal of clinical pharmacology*, 66(4), e70188.

Tang Z, et al. (2026) Optimal Dosage Justification for Datopotamab Deruxtecan in HR-Positive/HER2-Negative Breast Cancer Through Model-Informed Drug Development Approaches. *Clinical and translational science*, 19(2), e70493.

Hong Y, et al. (2025) Population Pharmacokinetic Analysis of Datopotamab Deruxtecan (Dato-DXd), a TROP2-Directed Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors. *CPT: pharmacometrics & systems pharmacology*, 14(12), 2149.

van Ede ES, et al. (2025) The Role of the BMI  $\geq$  40 kg/m<sup>2</sup> Criterion in ASA-PS Classification for Metabolic Surgery. *Obesity surgery*, 35(9), 3829.

Bruinsma FFE, et al. (2025) Refining the Quality Indicator Set from the Dutch Audit for Treatment of Obesity to Ensure Usefulness in Clinical Practice. *Obesity surgery*, 35(7), 2616.

Bruinsma FFE, et al. (2025) Variation in outcomes after metabolic bariatric surgery: multilevel analysis to assess the contribution of patient, surgeon, and hospital factors. *The British journal of surgery*, 112(10).

Liaqat M, et al. (2025) Sensitivity analysis for time-to-event data accounting for intra-individual variability in time-varying covariates with missing data. *Scientific reports*, 15(1), 27012.

Bruinsma FFE, et al. (2024) Optimizing Hospital Performance Evaluation in Total Weight Loss Outcomes After Bariatric Surgery: A Retrospective Analysis to Guide Further Improvement in Dutch Hospitals. *Obesity surgery*, 34(8), 2820.

Jacobs A, et al. (2023) Preoperative Weight Gain Is Not Related to Lower Postoperative Weight Loss, But to Lower Total Weight Loss up to 3 Years After Bariatric-Metabolic Surgery. *Obesity surgery*, 33(12), 3746.

Akpinar EO, et al. (2023) Weight recurrence after Sleeve Gastrectomy versus Roux-en-Y gastric bypass: a propensity score matched nationwide analysis. *Surgical endoscopy*, 37(6), 4351.

Liu X, et al. (2022) A single-nucleotide mutation within the TBX3 enhancer increased body size in Chinese horses. *Current biology : CB*, 32(2), 480.

Poelemeijer YQM, et al. (2018) A Dutch Nationwide Bariatric Quality Registry: DATO. *Obesity surgery*, 28(6), 1602.